FOR IMMEDIATE RELEASE

AMBIT BIOSCIENCES AND DAIICHI SANKYO, INC. ANNOUNCE TWO ORAL PRESENTATIONS AND ONE POSTER HIGHLIGHTING QUIZARTINIB TO BE PRESENTED AT THE 56TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY (ASH)

San Diego, CA and Parsippany, NJ – December 4, 2014 – Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, and Daiichi Sankyo, Inc. today announced acceptance of three abstracts with preliminary data highlighting Ambit's lead drug candidate, quizartinib. Presentations of the final data will be made during the 56th ASH Annual Meeting at the Moscone Center in San Francisco, CA on December 6-9, 2014. Oral presentations include the following:

Results of a Phase 1 Study of Quizartinib (AC220) as Maintenance Therapy in Subjects with Acute Myeloid Leukemia (AML) in Remission following an Allogeneic Hematopoietic Stem Cell Transplant: This is the first study conducted to determine whether or not quizartinib can be safely administered as post-transplant maintenance therapy in patients with AML. The data will be presented by Dr. Brenda M. Sandmaier, MD, at 10:45 am PT on Monday, December 8, in the West Building, 3002-3004.

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial: The primary objective of phase I is to determine the dose limiting toxicity and maximally tolerated dose of the combination of quizartinib (AC220) with either azacitidine (AZA) or low-dose cytarabine (LDAC); for phase II the primary objective is to determine the clinical activity of both combinations of quizartinib with AZA or LDAC in patients greater than 60 years with untreated MDS/CMML/AML, or adult patients receiving first salvage treatment. The data will be presented by Dr. Gautam Borthakur at 11:15 am PT on Monday, December 8, in the South Building, Gateway Ballroom 103.

The following poster will be presented by Ron Nepomuceno from Ambit Biosciences:

Differential Inhibition of FLT3-ITD, FLT3-WT, and KIT by Quizartinib as Assessed by Modified PIA Assay: Session Name: Acute Myeloid Leukemia: Clinical Studies: Poster I. Presentation on Saturday, December 6, 2014 from 5:30 – 7:30 pm PT at Moscone Center, North Building, Hall E.

The abstracts and posters can be accessed on the ASH website at http://hematology.org.

About Ambit Biosciences

Ambit, a member of the Daiichi Sankyo Group, is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently in a registrational Phase 3 clinical trial, referred to as QUANTUM-R, in patients with relapsed/refractory FLT3-ITD positive, acute myeloid leukemia (AML). Quizartinib is also being studied in newly diagnosed myeloid leukemia patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model," to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

###

Ambit Contact:
Marcy Graham
Executive Director, Investor Relations & Corp Comm
Ambit Biosciences Corporation
858-334-2125
mgraham@ambitbio.com

Kimberly Wix
Public Affairs
Daiichi Sankyo, Inc.
973-944-2338
kwix@dsi.com